文献速递冠心病心力衰竭与心肌病

人类急性心肌梗死后心脏αVβ3整合素表达

Cardiac αVβ3 integrin expression following acute myocardial infarction in humans.
PubMed 文献 · Heart · 2016-12-07

研究纳入21例ST段抬高型心肌梗死患者,于梗死后2周行18F-Fluciclatide PET/CT和钆增强MRI,9个月复查MRI;另纳入7例慢性完全闭塞患者和9名健康志愿者行单次PET/CT和MRI。结果显示急性梗死部位18F-Fluciclatide摄取增高,与功能恢复相关,而与梗死面积和炎症无关。

要点

  • 急性心肌梗死部位18F-Fluciclatide摄取较远端心肌和健康志愿者心肌增高。
  • 慢性完全闭塞患者陈旧梗死部位无18F-Fluciclatide摄取增高。
  • 18F-Fluciclatide摄取与节段功能恢复相关,与梗死面积和C反应蛋白无关。

核心结论

  • 18F-Fluciclatide在近期心肌梗死部位摄取增高,可作为心脏修复的生物标志物并预测恢复区域。

研究设计与样本

  • 21例ST段抬高型心肌梗死患者(前壁16例、侧壁4例、下壁1例)于梗死后2周行18F-Fluciclatide PET/CT和钆增强MRI,9个月后复查MRI。
  • 7例主要冠状动脉慢性完全闭塞的稳定患者和9名健康志愿者行单次PET/CT和MRI。

主要发现

  • 急性梗死部位18F-Fluciclatide摄取较远端心肌增高(TBRmean 1.34±0.22 vs 0.85±0.17,p<0.001)。
  • 急性梗死部位摄取较健康志愿者心肌增高(TBRmean 1.34±0.22 vs 0.70±0.03,p<0.001)。
  • 慢性完全闭塞患者陈旧梗死部位摄取与健康志愿者心肌相似(TBRmean 0.71±0.06 vs 0.70±0.03,p=0.83)。
  • 局部室壁运动减低节段摄取增高(室壁运动指数≥1 vs 0;TBRmean 0.93±0.31 vs 0.80±0.26,p<0.001)。
  • 功能恢复节段摄取增高(TBRmean 0.95±0.33 vs 0.81±0.27,p=0.002),且与区域恢复概率增加相关。

关键数值与推荐

  • 18F-Fluciclatide摄取与梗死面积无相关性(r=0.03,p=0.90)。
  • 18F-Fluciclatide摄取与炎症(C反应蛋白)无相关性(r=-0.20,p=0.38)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The αvβ3 integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether αvβ3 integrin expression determines myocardial recovery following MI. METHODS: 18F-Fluciclatide (a novel αvβ3-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR. RESULTS: 18F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBRmean 1.34±0.22 vs 0.70±0.03; p<0.001). There was no 18F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBRmean 0.71±0.06 vs 0.70±0.03, p=0.83). 18F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBRmean 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=-0.20, p=0.38), 18F-fluciclatide uptake was increased in segments displaying functional recovery (TBRmean 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery. CONCLUSION: 18F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery. TRIAL REGISTRATION NUMBER: NCT01813045; Post-results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Jenkins WS, Vesey AT, Stirrat C, et al. Cardiac αVβ3 integrin expression following acute myocardial infarction in humans. Heart. 2016. PMID: 27927700. doi:10.1136/heartjnl-2016-310115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。